Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project

Abstract

Purpose

Newborn screening (NBS) is performed to identify neonates at risk for actionable, severe, early-onset disorders, many of which are genetic. The BabySeq Project randomized neonates to receive conventional NBS or NBS plus exome sequencing (ES) capable of detecting sequence variants that may also diagnose monogenic disease or indicate genetic disease risk. We therefore evaluated how ES and conventional NBS results differ in this population.

Methods

We compared results of NBS (including hearing screens) and ES for 159 infants in the BabySeq Project. Infants were considered “NBS positive” if any abnormal result was found indicating disease risk and “ES positive” if ES identified a monogenic disease risk or a genetic diagnosis.

Results

Most infants (132/159, 84%) were NBS and ES negative. Only one infant was positive for the same disorder by both modalities. Nine infants were NBS positive/ES negative, though seven of these were subsequently determined to be false positives. Fifteen infants were ES positive/NBS negative, all of which represented risk of genetic conditions that are not included in NBS programs. No genetic explanation was identified for eight infants referred on the hearing screen.

Conclusion

These differences highlight the complementarity of information that may be gleaned from NBS and ES in the newborn period.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Comparison of conventional newborn screening (NBS) using dried blood spot versus exome sequencing (ES) results.

Data availability

The genomic data/analyses reported in this paper have been deposited in the NBSTRN LPDR (https://nbstrn.org/tools/lpdr) under accession identifier nbs000002.v1.p1. Data access is restricted; for information on how to request access, please contact corresponding author Monica Wojcik at monica.wojcik@childrens.harvard.edu or Pankaj Agrawal at pagrawal@enders.tch.harvard.edu.

References

  1. 1.

    Kemper, A. R. et al. Long-term follow-up after diagnosis resulting from newborn screening: statement of the US Secretary of Health and Human Services’ Advisory Committee on Heritable Disorders and Genetic Diseases in Newborns and Children. Genet. Med. 10, 259–261 (2008).

    Article  Google Scholar 

  2. 2.

    Fabie, N. A. V., Pappas, K. B. & Feldman, G. L. The current state of newborn screening in the United States. Pediatr. Clin. North Am. 66, 369–386 (2019).

    Article  Google Scholar 

  3. 3.

    Sahai, I. & Marsden, D. Newborn screening. Crit. Rev. Clin. Lab. Sci. 46, 55–82 (2009).

    CAS  Article  Google Scholar 

  4. 4.

    Wilcken, B. & Wiley, V. Newborn screening. Pathology. 40, 104–115 (2008).

    Article  Google Scholar 

  5. 5.

    Wojcik, M. H. et al. Beta-ketothiolase deficiency presenting with metabolic stroke after a normal newborn screen in two individuals. JIMD Rep. 39, 45–54 (2018).

    Article  Google Scholar 

  6. 6.

    Slaughter, J. L. et al. The effects of gestational age and birth weight on false-positive newborn-screening rates. Pediatrics. 126, 910–916 (2010).

    Article  Google Scholar 

  7. 7.

    Murry, J. B. et al. Reconciling newborn screening and a novel splice variant in BTD associated with partial biotinidase deficiency: a BabySeq Project case report. Cold Spring Harb. Mol. Case Stud. 4, a002873 (2018).

    Article  Google Scholar 

  8. 8.

    Verbeeten, K. C. et al. Carnitine uptake defect due to a 5’UTR mutation in a pedigree with false positives and false negatives on newborn screening. Mol. Genet. Metab. 129, 213–218 (2020).

    CAS  Article  Google Scholar 

  9. 9.

    American College of Medical Genetics Newborn Screening Expert Group. Newborn screening: toward a uniform screening panel and system--executive summary. Pediatrics. 11, S296–307 (2006).

    Google Scholar 

  10. 10.

    Parad, R. B., Kaler, S. G., Mauceli, E., Sokolsky, T., Yi, L. & Bhattacharjee, A. Targeted next generation sequencing for newborn screening of Menkes disease. Mol. Genet. Metab. Rep. 24, 100625 (2020).

    CAS  Article  Google Scholar 

  11. 11.

    Saunders, C. J. et al. Rapid whole-genome sequencing for genetic disease diagnosis in neonatal intensive care units. Sci. Transl. Med. 4, 154ra135 (2012).

    Article  Google Scholar 

  12. 12.

    Meng, L. et al. Use of exome sequencing for infants in intensive care units: ascertainment of severe single-gene disorders and effect on medical management. JAMA Pediatr. 171, e173438 (2017).

  13. 13.

    Gubbels, C. S. et al. Prospective, phenotype-driven selection of critically ill neonates for rapid exome sequencing is associated with high diagnostic yield. Genet. Med. 22, 736–744 (2020).

    Article  Google Scholar 

  14. 14.

    Kingsmore, S. F. et al. A randomized, controlled trial of the analytic and diagnostic performance of singleton and trio, rapid genome and exome sequencing in ill infants. Am. J. Hum. Genet. 105, 719–733 (2019).

    CAS  Article  Google Scholar 

  15. 15.

    Roman, T. S. et al. Genomic sequencing for newborn screening: results of the NC NEXUS Project. Am. J. Hum. Genet. 107, 596–611 (2020).

    CAS  Article  Google Scholar 

  16. 16.

    Adhikari, A. N. et al. The role of exome sequencing in newborn screening for inborn errors of metabolism. Nat. Med. 26, 1392–1397 (2020).

    CAS  Article  Google Scholar 

  17. 17.

    Ceyhan-Birsoy, O. et al. Interpretation of genomic sequencing results in healthy and ill newborns: results from the BabySeq Project. Am. J. Hum. Genet. 104, 76–93 (2019).

    CAS  Article  Google Scholar 

  18. 18.

    Bodian, D. L. et al. Utility of whole-genome sequencing for detection of newborn screening disorders in a population cohort of 1,696 neonates. Genet. Med. 18, 221–230 (2016).

    Article  Google Scholar 

  19. 19.

    Holm, I. A. et al. The BabySeq project: implementing genomic sequencing in newborns. BMC Pediatr. 18, 225 (2018).

    Article  Google Scholar 

Download references

Acknowledgements

M.H.W. is supported by K23 HD102589–01. Research reported in this publication was supported by the National Institutes of Health under award numbers R01HG009922, R01HL143295, U01TR003201, and U19HD077671. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Author information

Affiliations

Authors

Consortia

Contributions

Conceptualization: P.B.A., M.H.W. Data curation: M.H.W., T.Z., O.Z.B., C.G. Formal analysis: M.H.W., O.Z.B.,M.L. Project administration: C.G. Supervision: R.C.G., A.H.B., I.A.H., R.B.P., H.L.R. Writing—original draft: M.H.W., T.Z; Writing—review & editing: all authors.

Corresponding authors

Correspondence to Monica H. Wojcik or Pankaj B. Agrawal.

Ethics declarations

Ethics declaration

The BCH’s Institutional Review Board (IRB) and the Partners Human Research Committee (the IRB for BWH) approved this study and informed consent was obtained from all participants as required by the IRB.

Competing interests

R.C.G. has received compensation for advising the following companies: AIA, Grail, Humanity, Kneed Media, Plumcare, UnitedHealth, Verily, VibrentHealth, Wamberg; and is co-founder of Genome Medical, Inc. P.B.A. is on the Clinical Advisory Board of Illumina Inc. and GeneDx. H.L.R. is a compensated scientific advisory board member of Genome Medical. The other authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wojcik, M.H., Zhang, T., Ceyhan-Birsoy, O. et al. Discordant results between conventional newborn screening and genomic sequencing in the BabySeq Project. Genet Med (2021). https://doi.org/10.1038/s41436-021-01146-5

Download citation

Search

Quick links